uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington's DiseaseGlobeNewsWire • 09/02/26
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/YZacks Investment Research • 07/30/26
uniQure Announces Second Quarter 2026 Financial Results and Provides Company UpdateGlobeNewsWire • 07/29/26
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond HemgenixZacks Investment Research • 07/17/26
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?Zacks Investment Research • 07/17/26
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesGlobeNewsWire • 06/25/26
QURE Announces Initial Data on Gene therapy for Temporal Lobe EpilepsyZacks Investment Research • 06/22/26
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe EpilepsyGlobeNewsWire • 06/19/26